ACCURAY INC (ARAY) Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
Accuray Incorporated NASDAQ:ARAY Healthcare · Medical - Devices
Mkt Cap $16.72M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
Accuray granted inducement awards to Sofiane Laoussadi, its new Senior Vice President of Global Services & Solutions, as required under NASDAQ Listing Rule 5635(c)(4).
The awards comprise 650,000 restricted stock units and 650,000 performance-based restricted stock units at target, effective October 30, 2026, granted outside the equity plan but on terms consistent with the 2026 Equity Incentive Plan.
RSUs vest annually over four years beginning October 2027; PSUs vest based on fiscal 2028 performance criteria. This is a routine governance disclosure.
• 2d ago AI analysis › Press Release
Accuray to Report First Quarter Fiscal 2027 Financial Results on November 4, 2026
Accuray announced it will report first quarter fiscal 2027 results on November 4, 2026.
The company will host a conference call at 1:30 p.m. PT/4:30 p.m. ET, with a live webcast available on its investor relations website.
No financial figures were disclosed in this announcement; it is a scheduling notice only.
• 11d ago AI analysis › Press Release ● Major ⚠ 4
Accuray Announces Stockholder Approval of Key Financing-Related Proposals and Appointment of New Independent Director
Accuray stockholders approved all financing-related proposals at the October 6, 2026 special meeting, clearing the path for the TCW transaction.
The package includes a $40 million debt-for-preferred exchange, a $15 million TCW equity investment, access to up to $5 million of delayed draw term loan, covenant relief through December 31, 2027, and a discretionary reverse stock split between 1-for-15 and 1-for-40.
The company also appointed Richard A. ("Randy") Meier, a 30-year medtech and healthcare executive, to its board, effective immediately.
The deal materially improves liquidity but signals balance-sheet stress, with lender-driven governance changes and a steep potential reverse split ratio.
• 26d ago AI analysis › Press Release ⚠ 1
Accuray and Samsung NeuroLogica Advance Volumetric Imaging Collaboration for the Accuray CyberKnife® Platform
Accuray entered into agreements with Samsung NeuroLogica to pursue advanced volumetric imaging capabilities for the CyberKnife System, announced alongside the ASTRO Annual Meeting.
The collaboration pairs Samsung's mobile CT expertise with Accuray's robotic radiosurgery and motion-management know-how; The Royal Marsden is the first center worldwide participating, with clinical endorsements from MedStar Georgetown.
There is no commercial product offering or financial commitment yet — development will proceed through phased evaluation subject to regulatory requirements, making this a strategic rather than near-term revenue catalyst.
• 1mo ago AI analysis › Press Release ⚠ 2
Accuray and RaySearch Agree to Collaboration Integrating RayStation Software with Accuray Platforms to Accelerate Accuray's Online Adaptive Capabilities
Accuray and RaySearch Laboratories signed a definitive agreement for an expanded collaboration integrating RayStation treatment planning software with Accuray's radiation therapy platforms to accelerate Accuray's online adaptive radiation therapy capabilities.
The initial focus is Accuray's Radixact platform, with the solution to be extended to CyberKnife in the future, and RayCare technology will be used to simplify connectivity between clinical systems and support adaptive workflows.
As part of the deal, Accuray agreed to purchase specified RayStation licenses with a total order value of USD $8 million, and the parties will jointly market and support the resulting online adaptive solutions.
Accuray CEO Steve LaNeve framed the partnership as part of the company's growth strategy to accelerate innovation while focusing on core strengths in imaging and treatment delivery.
• 1mo ago AI analysis › Press Release ⚠ 4
Accuray Reports Fourth Quarter and Fiscal 2026 Financial Results
Accuray reported fiscal Q4 revenue of $100.9 million, down 21% year-over-year, driven by a 42% decline in product revenue, though service revenue grew 6%.
The company highlighted that its transformation plan delivered $20 million in cost savings, exceeding its $12 million target, and announced a financing transaction with TCW Asset Management to strengthen liquidity and reduce leverage.
Despite these operational improvements, the company posted a net loss of $1.9 million for the quarter and $49.2 million for the full year, and it withdrew formal fiscal 2027 guidance due to geopolitical and macroeconomic uncertainties.
• 2mo ago AI analysis › Press Release
Accuray Advances Strategic Priorities Through Key Executive Leadership Appointments
Accuray appointed Todd Brown to lead the newly created Enterprise Performance Optimization organization and named Sofiane Laoussadi as Senior Vice President, Global Services & Solutions.
The appointments are intended to accelerate the company's Transformation Phase II priorities, including improving operational execution, lowering cost structure, and enhancing margins.
Brown and Laoussadi both bring experience from GE Healthcare; their focus will be on driving cash flow, supply chain efficiency, and expanding the services business, which generated 57% of consolidated net revenues in fiscal year 2026.
• 2mo ago AI analysis › Press Release
Accuray to Report Fourth Quarter Fiscal 2026 Financial Results on August 19, 2026
Accuray announced it will report fiscal fourth quarter 2026 financial results on August 19, 2026, via a conference call scheduled for 1:30 p.m. PT.
A live webcast will be accessible through the company's investor relations website, with a replay available for one week following the call.
The announcement provided contact details for investor and media inquiries but did not contain preliminary financial figures or business outlooks.
• 2mo ago AI analysis › Press Release ● Major ⚠ 3
Accuray Announces Plan Involving Financial Strengthening, Strategic Partnerships, Technology Rollouts, and Operational Initiatives to Drive Long-Term Value Creation
Accuray announced a definitive financial restructuring agreement with lender TCW Asset Management, involving a $40 million debt-for-equity swap and a $15 million equity investment to bolster liquidity.
The transaction provides a covenant holiday through 2027 and restructures the board to seven members, with TCW appointing two directors, while also mandating a reverse stock split to maintain listing compliance.
Concurrently, the company signed non-binding LOIs with Samsung HME America and RaySearch Laboratories to advance imaging and treatment capabilities, alongside expanded operations with Tata Consultancy Services.
• 3mo ago AI analysis › Press Release
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
Accuray appointed Paul Miele as Chief Commercial Officer and David Shin as Chief Legal Officer, effective May 29, 2026.
As inducement awards required by NASDAQ Listing Rule 5635(c)(4), Miele received 650,000 RSUs and 650,000 PSUs, while Shin received 375,000 RSUs and 375,000 PSUs.
The awards vest over time subject to continued employment and, for the PSUs, performance criteria determined by the Compensation Committee.
• 5mo ago AI analysis › Press Release
Accuray and the University of Wisconsin-Madison Announce Master Research Agreement to Improve Personalized Care for Patients with Cancer
Accuray has entered a 10-year master research agreement with the University of Wisconsin-Madison to advance personalized cancer treatments using its Stellar adaptive radiation therapy platform.
The collaboration builds on a decades-long history, dating back to the invention of the TomoTherapy system by UW Professor Thomas Mackie, and will focus on clinical research, education, and the development of adaptive therapies.
This partnership reinforces Accuray’s position in precision radiation oncology and provides a structured pathway for translating academic research into clinical applications.
• 5mo ago AI analysis › Press Release ● Major ⚠ 5
Accuray Reports Fiscal 2026 Third Quarter Financial Results
Accuray reported Q3 revenue of $104.8 million, down 7% year-over-year, and withdrew its FY26 financial guidance due to geopolitical uncertainty in the Middle East impacting shipments and installations.
Adjusted EBITDA fell to $3.8 million from $6.0 million in the prior year, though the company noted its transformation plan is ahead of schedule with $10 million in cost improvements realized.
Order backlog decreased 21% to $356.2 million, while cash and cash equivalents stood at $38.1 million at quarter end.
• 5mo ago AI analysis › Press Release
Accuray to Report Third Quarter Fiscal 2026 Financial Results on May 6, 2026
Accuray Incorporated announced it will report financial results for the third quarter of fiscal 2026 on May 6, 2026.
The conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET and will be hosted by company management.
A live webcast and dial-in replay will be available via the company's Investor Relations section.
• 6mo ago AI analysis › 
